Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

modernretina.com image

News from modernretina.com

See all of modernretina.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

In total, 152 have been published by modernretina.com which Ground News has aggregated in the past 3 months.

The Ground News media bias check for modernretina.com is unknown. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

modernretina.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about modernretina.com

Where is modernretina.com located?modernretina.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top modernretina.com News

A Large Genome-Wide Association Study of Age-Related Macular Degeneration Highlights Contributions of Rare and Common Variants

A Large Genome-Wide Association Study of Age-Related Macular Degeneration Highlights Contributions of Rare and Common Variants

100% Center coverage: 2 sources

Iris Heid, Gonçalo Abecasis, Sudha Iyengar and colleagues report the results of a large genome-wide association meta-analysis of macular degeneration based on over 43,000 subjects. They identify 16 new risk loci, including some very rare coding variants. Advanced age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, with limited therapeutic options. Here we report on a study of >12 million variants, including 1…See the Story

57% of patients say yes to AI in the exam room if it means more time with their doctor

Artificial Intelligence

57% of patients say yes to AI in the exam room if it means more time with their doctor

100% Center coverage: 1 sources

A new ModMed survey finds most patients support AI in the exam room, but only for tasks that reduce screen time and build human connection.See the Story

Stem Cell and Gene Therapy Innovations Poised to Transform Medicine

Stem Cell and Gene Therapy Innovations Poised to Transform Medicine

The global stem cell market, valued at $15.10 billion in 2024, is on a trajectory to nearly double to $28.89 billion by 2030, growing at an 11.4 percent compound annual growth rate. This expansion is fueled by significant advancements in regenerative medicine, increased investments, and the development of therapies targeting diseases like cancer, autoimmune disorders, and genetic conditions. Stem cells’ unique ability to repair and regenerate da…See the Story

Improving retinal drying and treatment durability with second-generation anti-VEGF therapies

Recapping a recent conversation led by Dilsher S. Dhoot, MD.Read Article

Sanaregen Vision Therapeutics Invites Prospective Investors to Reserve Stock Shares

Sanaregen Vision Therapeutics invites investors to reserve shares as it prepares for an equity crowdfunding campaign to advance retinal disease treatments.See the Story

Drugs to treat GA: Yes, please!

Patients are highly motivated to slow disease progression with GA drugs and healthy lifestyle.Read Article

Retinal Degeneration Fund providing funding to Opus Genetics to support OPGx-MERTK program

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants in the MERTK gene.See the Story

Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.Maryland · Maryland See the Story

CTS 2025: Christine Kay, MD, on OPGx-LCA5 clinical results translated into real-life changes

Phase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.Maryland · Maryland Read Article

PYC works to meet FDA alignment for its investigational drug candidate, VP-001

PYC Therapeutics advances VP-001 for retinitis pigmentosa, securing FDA guidance for its upcoming registrational trial design and study parameters.United States · United States Read Article

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001

Perfuse Therapeutics reveals promising Phase 2 trial results for PER-001, a potential treatment for glaucoma and diabetic retinopathy.See the Story

Breaking News Topics Related to modernretina.com